Best Grants for Preschools in Louisiana

Our Consortium

ROAR (Rare Organic Acidemias Research) is a multi‑center study that brings together patients, families, clinicians, and researchers to better understand rare organic acidemias such as PA, MMA, GA‑1, IVA, and others. Our goal is to improve lifelong care and future treatment options for the rare disease community.

ROAR works in partnership with patient organizations, clinicians, and research networks to ensure that study findings are shared, accessible, and meaningful. Families play a central role in shaping our questions and informing our direction.

Rare Organic Acidemias Research (ROAR) Consortium Pilot and Feasibility Grants

The overall mission of the ROAR pilot & feasibility grant is to support small projects which advance diagnosis, enhance clinical trial readiness, and improve therapies and outcomes for individuals with organic acidemias. Potential pilot projects may include data-mining of existing data, genotype-phenotype correlations, observational studies, patient-reported outcomes assessments, focus groups with patients and advocacy groups, interventional clinical trials (with prior NIH approval), biomarker studies, ancillary studies to ROAR clinical projects, or other similar projects. Upon completion of funding, we expect that the data generated from ROAR pilot projects will be leveraged for larger grant applications and larger projects within and outside the consortium. Moreover, we expect that the data generated will inform the design of future clinical trials and clinical studies in organic acidemias and ultimately, will impact the lives of individuals with organic acidemias by improving the diagnosis, management, and treatment for these disorders. 

Annual funding of up to $40,000 (total cost, including indirect costs) is available to support one pilot project for a one-year period. The ROAR Consortium intends to fund at least 1 award this cycle starting on October 15, 2026.

Pediatric Hidradenitis Suppurativa Challenge Grant

Hidradenitis suppurativa (HS) is a devastating chronic inflammatory disease that manifests as recurrent painful nodules under the skin in the intertriginous areas of the body. It is associated with significant impacts on quality of life, psychosocial well-being, and long-term health outcomes of patients as well as consequences for families and caregivers. HS is prevalent, affecting between 1 and 4% of the population beginning in adolescence and persisting into adulthood. Despite the impact of HS, it remains underdiagnosed, undertreated, and understudied particularly in the pediatric and adolescent populations. Contributing to this dynamic are unknowns related to a complex disease etiology, stigma associated with HS symptoms (e.g., sweating, itching, and scarring commonly in the genital region), and limited treatment options to date with even fewer available for children under the age of 12.

To address the needs of children and adolescents living with HS, the Pediatric Dermatology Research Alliance (PeDRA), HS Connect, and the HS Foundation are offering the 2026 Pediatric HS Challenge Grant to support an early-to-mid career investigator for a one-year project focused on a high-priority, patient-centric research topic.

Focus

Proposals should address one or more of the following high-priority research topics:

• Predicting treatment effectiveness and risk utilizing real world evidence and/or experience
• Early disease and factors involved in severe disease development
• Optimizing surgical and procedural approaches to minimize pain, shorten healing time, and reduce recurrence
• Improving recruitment of diverse and representative populations for clinical studies, trials and advanced therapeutics

Funding:

• Up to $50,000 to support one year of research
• One award anticipated for this funding cycle

The Alpha Omega Alpha/Pharos Poetry Award

To encourage students to write effective poetry. Winning poems are published in The Pharos.

The Award

Up to 5 poems will receive a $1,500 award. The winning entries will be published in The Pharos.

Summer Medical Internship Program (SMIP)

Fosters an interest in research by funding a summer research project conducted by a medical student.

The SIR Foundation Summer Medical Internship Program introduces medical students to interventional radiology research and medical device development. The goal of this program is to foster an interest in research by funding a summer research project conducted by a medical student.

Students applying for the program must show strong potential for a career in IR with proven academic success. Selected students will have an opportunity to intern with an interventional radiologist research mentor or corporate research and development mentor for 8 weeks during the summer.

SIR Foundation will provide a $6,000 stipend to help ease the financial burdens throughout their internship experience.

• Budget: Up to $6,000
• Grant Length: Eight weeks

Hilcorp Future Leaders of America Scholarship

Benefiting select communities across the United States where Hilcorp operates.

The Hilcorp Future Leaders of America Scholarship Program was developed to give back to the communities in which Hilcorp Energy Company operates to develop future leadership talent as the next innovators, educators, and business leaders.

Award Amount

Multiple scholarships awarded annually. The scholarship is comprised of up to four (4) annual awards of $2,500, for a total award of up to $10,000.

The four annual (4) awards may be received over a period of up to 6 years, allowing for deferment if needed.

GBA1 Parkinson's Disease Research Catalyst Program

The GBA1-PD Research Catalyst Program seeks to build a deeper, globally integrated understanding of GBA1-associated Parkinson’s disease by aligning efforts across geographies and maximizing the value of shared datasets and research assets. Funding will support hypothesis- driven projects with an emphasis on integrative, cross-cohort analyses and the systematic characterization and standardization of models to enable broad use by the research community.

Funding

Duration: 12 to 24 months

Award Amount: Up to $300,000. Requested support should be commensurate with work proposed.

These budgets include direct and indirect costs. For academic and for-profit institutions, no more than 15% or 10%, respectively, may go to indirect costs. 

Patrick J. Kiley / Houston AGC Scholarship

Benefiting employees, dependents of employees, and/or interns of AGC Houston member firms OR students involved in AGC Student Chapters.

Award Amounts

Multiple awards are given each year. Scholarship award amounts will vary for each selected scholarship recipient.

Investigating the Benefit of Early Treatment with Ritlecitinib in Alopecia Areata: A Real-World Evidence Approach

Alopecia Areata (AA) is a chronic, immune-mediated condition causing nonscarring hair loss that affects about 2% of the global population and can lead to substantial psychosocial burden if disease is severe and untreated. The treatment landscape has recently evolved with the approval of ritlecitinib, a systemic therapy for severe AA in adults and adolescents aged 12 years and older, based on efficacy demonstrated in the ALLEGRO phase 2b/3 program.

Despite this advance, important questions remain regarding the optimal timing of therapy initiation. Emerging post-hoc analyses from the ALLEGRO program indicate that patients with shorter disease duration and lower baseline severity achieve higher response rates, suggesting that earlier intervention with ritlecitinib may lead to improved outcomes.

Geographic Scope

United States 

Funding Range and Project Length

Individual projects requesting up to $100,000 USD will be considered.

Maximum project length is 24 months.

Hemophilia Fellowship

This competitive grant program seeks to support an institution-based fellowship that emphasizes shared decision making (SDM), patient education, and multidisciplinary team-based care. The intent is to strengthen the hemophilia care through equitable education, and patient-centered shared decision making in a rapidly evolving treatment landscape.

Geographic Scope

• United States 

Funding Range and Project Length

• Grant funding is available to support a one year fellowship up to $100.000 USD. 

Accelerating the Development of Combined CGM–Pump Devices

A combined continuous glucose monitor (CGM) and insulin pump device represents an innovative approach to simplifying diabetes management by integrating two essential technologies into a single device. This approach has the potential to improve quality of life for people with type 1 diabetes (T1D) by reducing the burden associated with wearing and managing multiple devices.

Despite this promise, the development of combined CGM–pump devices presents technical and commercialization challenges. These include the need for further advances in device compatibility and lifespan, system reliability, and scalable manufacturing, while maintaining affordability and broadaccessibility. In addition, a potential insulin dilution effect may require adjustment of the CGM algorithm.

Breakthrough T1D invites applications for research and development projects that address key technical, clinical, and translational challenges related to combined CGM–pump devices, with the goal of accelerating their development and improving outcomes for people living with T1D.

In response to this announcement, applications may request up to a total of $900,000 USD for up to three years. 

OREF/Musculoskeletal Transplant Foundation Research Grant

Solicits investigator-initiated proposals focusing on research in the science of biologic – reconstruction, bone regeneration, transplantation - allografts, and including stem cells for graft transplantation.

The NEA Arts and Artifacts International Indemnity Program, administered by the National Endowment for the Arts, provides financial protection for museums exhibiting significant art and artifacts. Launched in 1975, it minimizes insurance costs for international exhibitions. The program allows U.S. entities to receive indemnity for works of art while on display in the U.S. Applications are assessed by expert panels, ensuring a thorough review process before approvals or conditional notices are issued.

The FY25-FY26 Advanced Transportation Technology and Innovation (ATTAIN) grant program aims to enhance transportation through the deployment of innovative technologies. It focuses on improving safety, mobility, and efficiency while fostering economic competitiveness. Projects funded will prioritize core infrastructure improvements and address roadway congestion, aligning with the Trump Administration's goals. The program emphasizes economic opportunities and community benefits, ensuring that selected projects contribute positively to families and communities, ultimately enhancing their quality of life.

The NEA Arts and Artifacts International Indemnity Program, established in 1975, supports the exhibition of significant art and artifacts by minimizing insurance costs for international exhibitions. Administered by the National Endowment for the Arts, it covers U.S. owned art during exhibitions in the country. The program evaluates applications through advisory panels and the Federal Council on the Arts and Humanities, ensuring that vital cultural works are accessible while providing necessary financial protections.

The NEA Arts and Artifacts Domestic Indemnity Program, administered by the National Endowment for the Arts, ensures that U.S. museums can exhibit significant art and artifacts without the burden of high insurance costs. Established in 1975, it provides indemnity against loss or damage, promoting access to cultural heritage. The program evaluates applications through expert advisory panels and typically meets three to six months after deadlines to decide on indemnity requests, thereby supporting the arts and enriching public engagement.

The NEA Arts and Artifacts Domestic Indemnity Program provides museums and cultural institutions in the U.S. with financial protection against loss or damage to significant artworks during exhibitions. Established in 1975 and expanded in 2007, the program aims to enhance public access to art by minimizing insurance costs. Managed by the National Endowment for the Arts, it involves thorough evaluations by expert panels to ensure eligibility and compliance, facilitating the safe display of invaluable cultural treasures.

The National Institute of Environmental Health Sciences (NIEHS) is seeking applications for research coordination and data support under the Health and Extreme Weather initiative. This funding opportunity aims to engage NIH grantees and the broader community by sharing best practices, developing training resources, and facilitating access to health and environmental data. The initiative will enhance collaboration, reduce duplication, and promote data standards to support impactful research and infrastructure activities.

The National Institute of Environmental Health Sciences (NIEHS) is launching a funding opportunity for research hubs focused on the health impacts of extreme weather. This initiative encourages multidisciplinary teams to engage with community partners on issues such as wildfire smoke and extreme heat. Emphasizing collaboration, the program aims to develop scalable solutions and measurable public health outcomes, leveraging resources and expertise across institutions to address climate-related health challenges effectively.

The SPARK-EHS initiative aims to broaden the reach of NIEHS training by launching innovative environmental health programs for predoctoral trainees at institutions without recent NIEHS T32 funding. This initiative focuses on research regarding the impact of the environment on biological systems and seeks to translate findings into practical health solutions. Eligible institutions will receive support for developing and implementing these targeted training programs, fostering advancements in environmental health research.

The National Institute of Allergy and Infectious Diseases (NIAID) is funding research to enhance drug susceptibility testing (DST) for mycobacteria. This initiative aims to improve testing for tuberculosis (TB) and non-tuberculous mycobacterial (NTM) infections, which are on the rise. Current methods are slow and ineffective against drug-resistant strains, making rapid DSTs essential for effective treatment and reducing transmission rates. Innovative approaches, including rapid genotypic and phenotypic methods, will be supported to address these challenges.

The Childhood Asthma in Urban Settings Clinical Research Network (CAUSE) aims to enhance asthma prevention and treatment in economically disadvantaged pediatric populations. Funded by the NIH, CAUSE supports multi-site clinical studies to identify innovative strategies and treatment targets for asthma. Utilizing systems biology, the network seeks to discover specific disease endotypes suitable for new therapeutic approaches, addressing the high burden of asthma in urban settings.

The BRAIN Initiative seeks to develop innovative tools and approaches for neuroscience research, focusing on cell-specific and circuit-specific processes within the central nervous system. This initiative encourages projects that enhance our understanding of brain architecture and function through novel technologies for characterizing neural components and advancing methods for recording and modulating neural activity. Applications are invited to address significant challenges and promote transformative breakthroughs in neuroscience.

The National Institute of Mental Health is inviting research applications for the AIDS Research Center program, which includes Developmental Centers and full Research Centers. This initiative aims to enhance interdisciplinary HIV/AIDS research through collaboration and innovative approaches across various scientific domains. The program emphasizes alignment with national strategies and encourages applications from teams skilled in fostering partnerships with diverse stakeholders. Although applications are currently not being solicited, this notice allows potential applicants time to prepare strong proposals.

The National Institute of Allergy and Infectious Diseases (NIAID) is advancing research on immune tolerance through its Collaborative Network. This program aims to clarify the mechanisms of immune tolerance and develop interventions for related diseases, including transplant rejection and autoimmune disorders. Key objectives include conducting clinical trials on tolerogenic strategies and refining immune assays. This initiative is supported by regulations under the Public Health Service Act, ensuring a structured approach to improving patient outcomes.

The Clinical Data, Safety and Statistical Centers (CDSSC) program, supported by the National Institute of Allergy and Infectious Diseases (NIAID), aims to enhance clinical research through comprehensive support. This includes statistical analysis, protocol development, and oversight of safety monitoring in studies related to asthma, autoimmune diseases, and transplantation. By coordinating these efforts, the program seeks to facilitate impactful research outcomes and improve public health outcomes through informed data-driven decisions.

The Translational Transplantation Tolerance Cooperative Study Group, supported by the National Institute of Allergy and Infectious Diseases, aims to advance transplant tolerance strategies that promote long-term graft survival without lifelong immunosuppression. This initiative focuses on developing, optimizing, and evaluating methods to induce immune tolerance in allogeneic transplants through collaborative efforts across multiple centers, utilizing translationally relevant models to ensure effective outcomes.

The NIAID aims to enhance our understanding of the interplay between chronic and infectious diseases through innovative precision systems biology research. By utilizing advanced technologies such as multi-omics and artificial intelligence, the initiative focuses on uncovering critical pathways that connect infections to chronic health issues. This multidisciplinary approach leverages longitudinal patient data to inform and improve prevention and treatment strategies, ultimately seeking to provide insights into disease progression and host-pathogen interactions.